Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...

But it remains costly — and controversial Health Canada approved a prescription esketamine nasal spray called Spravato in ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Harmony's Martinsburg clinic now offers SPRAVATO®, an FDA-approved nasal spray for treatment-resistant depression, providing fast-acting symptom relief. MARTINSBURG, WV, UNITED STATES ...

Why We Need Fast-Acting Anxiety Relief Now More Than Ever Anxiety isn’t just feeling nervous before a big event—it can be relentless, overwhelming, and even debilitating. Traditional treatments like ...

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...

Spravato (esketamine) was approved by the EMA in December as an adjunctive, add-on therapy for people with serious depression who don’t respond to treatment with at least two from the current ...

“A lot of insurance payers interpreted this to mean that in order to get covered for the treatment, you also needed to start a new oral antidepressant.” Those requirements can make it more difficult ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...